Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 04, 2015 3:44 AM ET

Biotechnology

Company Overview of Quanterix Corporation

Company Overview

Quanterix Corporation develops and provides ultra-sensitive diagnostic platform for measuring individual proteins. The company offers Single Molecule Array technology that enables the detection and quantification of biomarkers in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more; assay kits; and consumables. Its products are used in life science research, oncology, neurology, inflammatory disease, and infectious disease applications. Quanterix Corporation was formerly known as Digital Genomics Inc. and changed its name to Quanterix Corporation in August 2007. The company was founded in 2007 and is based in Lexington, Massachusetts.

13 Hartwell Avenue

Suite B14201

Lexington, MA 02421

United States

Founded in 2007

Phone:

617-301-9400

Fax:

617-301-9401

Key Executives for Quanterix Corporation

Executive Chairman and Chief Executive Officer
President and Director
Co-Founder, Chairman of Scientific Advisory Board and Director
Age: 62
Chief Financial Officer and Vice President of Finance & Administration
Chief Technology Officer and Vice President of Research
Compensation as of Fiscal Year 2015.

Quanterix Corporation Key Developments

Quanterix Corporation Announces Commercial Availability of its Multiplex Panels and Homebrew Kits for Biomarker Discovery and Validation

Quanterix Corporation announced commercial availability of its multiplex panels, providing users with the ability to develop their own multiplex assays using the company’s ultra-sensitive Simoa technology. This allows users to achieve similar sensitivity with each marker in a multiplex panel as they would if they were to test individual assays. The company has also developed a convenient multiplex homebrew kit, allowing customers to use their own antibody pairs to develop custom multiplex Simoa panels, providing unlimited flexibility and significant cost savings. Researchers and clinicians want the ability to test for several different biomarkers on a small sample, making it possible to consider alternative, less invasive samples than the traditional blood test. The company's menu of Simoa assay kits has been growing rapidly and has now reached 30 assays, including markers for oncology, cardiology, neurology, infectious disease and inflammatory disease, all of which allow researchers to measure the associated biomarkers at levels that were impossible to measure until now. The first commercially available multiplex kits are 3-plex panels of cytokines, which are very useful for measuring inflammatory response across a wide range of conditions. These new panels are composed of individual cytokines that have been most popular with Simoa customers over the past year in singleplex format. The normal healthy range for many cytokines is close to the limit of detection of conventional immunoassay measurement techniques. Because of this, the sensitivity provided by Simoa allows researchers to measure both healthy and sick subjects with confidence, leading to a significant increase in demand for Simoa cytokine assays over the past year.

Quanterix Appoints SCRUM Inc. for Simoa Distribution in Japan

Quanterix Corporation announced it has appointed SCRUM Inc. as an exclusive distributor for sales and support of its Simoa technology for the research market in Japan.

Myriad RBM Uses Quanterix’ Simoa Technology to Launch New Ultrasensitive Immunoassay Services

Quanterix Corporation announced that Myriad RBM will use Quanterix' Simoa technology to launch new ultrasensitive immunoassay services in its CLIA-certified laboratory in Austin, Texas. Using Simoa, the company will have the ability to accurately measure protein biomarkers that were previously difficult or even impossible to detect in blood samples.

Similar Private Companies By Industry

Company Name Region
Lazarus Therapeutics LLC United States
Innovative Biologics, Inc. United States
Anti-Microbial Solutions, LLC United States
Verex Laboratories, Inc. United States
Sustained Release, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Quanterix Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.